Additional file 1: Figure S1. of Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression

Uptake Time and Spleen SUVMax % Δ Post SSA (n = 20, 1 patient prior splenectomy). (TIFF 1294 kb)